Transcarent, led by Livongo Health founder Glen Tullman, bought public market competitor Accolade in January for $621 million, about half of Accolade's IPO price when the benefits navigator went ...

Security player’s distributor views move as a moment that validates the market as well as its involvement with the vendor.

We built our IPO process in partnership with the investment banking community, ensuring that they have the control and information they need to successfully open your IPO. Nasdaq’s best-in-class ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

Beyond domestic benefits, the IPO boom could fuel global expansion for Saudi-based companies. Increased capital provides firms with the financial firepower for cross-border acquisitions, market ...